MET L1213F
| Gene | MET |
| Variant | missense |
| Amino Acid Change | L1213F |
| DNA Change (Coding Nucleotide) | 3637C>T |
| Transcript ID (GRCh37/hg19) | ENST00000318493 |
| Codon | 1213 |
| Exon | 18 |
| Genomic Coordinates (GRCh37/hg19) | 7:116422102-116422102 |
| COSMIC ID | 3724578 |
| Germline/Somatic? | Somatic |
Pertinent Negative In
| Tumor Type | Primary Site |
|---|
Interpretations
Sort by
Page
Show
Tier 2|
Primary Sites
Tumor Types
Interpretation
Activating somatic mutations in the tyrosine kinase domain of MET are found in about 10-15% of sporadic papillary renal cell carcinoma (pRCC). MET mutations are predominantly associated with Type 1 pRCC tumors. The responses to foretanib an oral inhibitor of MET and other tyrosine kinases including VEGFR2, have been described in patients with papillary renal cell cancer.
Last updated: 2020-07-24 14:52:06 UTC
Read More